Hematology - Adzynma Utilization Management Medical Policy
Customize your policy alerts
Sign up for UCare Policy 327 alerts
Get alerted when Policy 327 changes without checking for updates manually.
Monitor payer policy activity
Prior authorization and medical-benefit coverage of Adzynma for UCare members with congenital thrombotic thrombocytopenic purpura across pediatric and adult populations and all UCare plans.
The criterion requiring a pathogenic variant in the ADAMTS13 gene was revised by removing the phrase "or a mutation," and the related note was revised accordingly.
Recommended Authorization Criteria
Adzynma is not recommended for circumstances that are not listed in the Recommended Authorization Criteria. The criteria may be updated as new published data become available.
Dosing and Laboratory Requirements
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.